Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accentia Biopharmaceuticals has agreed to market Collegium Pharmaceuticals' investigational intranasal steroid intended for the treatment of symptoms of seasonal and perennial allergic rhinitis in the US.
Subscribe to our email newsletter
This license will expand Accentia’s pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market.
Collegium plans to file a supplemental new drug application (sNDA) in 2006 for the patent-pending aqueous nasal spray formulation.
According to Accentia, the intranasal steroid market in the US represents approximately $2.7 billion dollars in annual sales. The primary competition for this market is prescription non-sedating oral antihistamine products which have annual sales in excess of $4 billion dollars in the US.
“We anticipate that over the next several years many of the non-sedating antihistamines will migrate to the over-the-counter marketplace. This anticipated shift in the market may benefit growth in the intranasal steroid prescription market,” said Michael Heffernan, president of Collegium. “We believe that our new product will have a favorable profile within the nasal steroid market.”